BEDOUKIAN RESEARCH INC. PARTNERS WITH INSCRIPTA TO SUSTAINABLY DEVELOP AND MANUFACTURE NATURALLY PRODUCED INGREDIENTS
July 19th, 2023: Pleasanton, CA and Danbury, CT: Bedoukian Research Inc. (BRI), a leading global supplier of flavor & fragrance...
Read More
INSCRIPTA® ACQUIRES INFINOME BIOSCIENCES AND SESTINA BIO TO ADVANCE SUSTAINABLE BIOMANUFACTURING
With the addition of Infinome and Sestina Bio, Inscripta adds to its portfolio of cutting-edge technologies for biomanufacturing products for...
Read More
KALSEC® PARTNERS WITH INFINOME™ BIOSCIENCES TO SUSTAINABLY DEVELOP AND MANUFACTURE PRECISION FERMENTATION PRODUCTS
Through advanced technology and processes, Infinome is creating sustainable manufacturing solutions for Kalsec.
Read More
Aldevron Licenses the Manufacturing of MAD7, a Type-V CRISPR Nuclease From Inscripta
A partnership between two CRISPR pioneers will provide the global scientific community with GMP MAD7™ Nuclease
Read More
Inscripta® Appoints Kristala Prather, PhD to its Board of Directors
Inscripta adds a distinguished MIT Professor and synthetic biology pioneer, Dr. Kristala Prather, to the Board of Directors.
Read More
Hunterian Medicine® Licenses Inscripta’s MAD7™ Nuclease to Advance Gene Editing Research and Development
Inscripta and Hunterian pioneer new program to provide access to novel CRISPR enzymes for biotherapeutic development
Read More
Inscripta® Announces the First Commercial Shipment of Its Onyx® Digital Genome Engineering Platform and Closes $150 Million in New Financing
GeneMill at the University of Liverpool receives first benchtop Onyx platform in Europe Financing round led by Fidelity and T....
Read More
Inscripta® Launches the World’s First Benchtop Platform for Digital Genome Engineering
The Onyx® platform enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a...
Read More
In the First Year of Release, Inscripta®’s MAD7™ CRISPR Enzyme is Widely Adopted by the Gene-Editing Community
Existing investors contribute an additional $30 million to accelerate tools that will revolutionize genomic research
Read More
Inscripta® Granted Patents for CRISPR Gene-Editing Systems
New data shows Inscripta’s MADzymes edit in mammalian cells
Read More
- 1
- 2